[go: up one dir, main page]

HK1094972A - Biologically active peptide vapeehptllteaplnpk derivatives - Google Patents

Biologically active peptide vapeehptllteaplnpk derivatives Download PDF

Info

Publication number
HK1094972A
HK1094972A HK07102489.7A HK07102489A HK1094972A HK 1094972 A HK1094972 A HK 1094972A HK 07102489 A HK07102489 A HK 07102489A HK 1094972 A HK1094972 A HK 1094972A
Authority
HK
Hong Kong
Prior art keywords
vapeehptllteaplnpk
derivatives
biologically active
active peptide
peptide
Prior art date
Application number
HK07102489.7A
Other languages
Chinese (zh)
Inventor
Wai Ming Wong
Kong Lam
Original Assignee
Cms Peptides Patent Holding Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cms Peptides Patent Holding Company Limited filed Critical Cms Peptides Patent Holding Company Limited
Publication of HK1094972A publication Critical patent/HK1094972A/en

Links

Abstract

Peptides derived from the peptide CMS-010, which has the formula VAPEEHPTLLTEAPLNPK, are disclosed with their use as pharmaceutical compositions. A method is also disclosed for making a pharmaceutical composition comprising providing a peptide derived from CMS-010 and mixing said peptide with a pharmaceutical acceptable carrier.
HK07102489.7A 2004-04-28 2005-04-25 Biologically active peptide vapeehptllteaplnpk derivatives HK1094972A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60/566,455 2004-04-28

Publications (1)

Publication Number Publication Date
HK1094972A true HK1094972A (en) 2007-04-20

Family

ID=

Similar Documents

Publication Publication Date Title
WO2004074244A3 (en) Pyrimidine compounds
WO2006034039A3 (en) Substituted morphinans and methods of their use
TW200608973A (en) Rapamycin polymorph Ⅱ and uses thereof
GB0519272D0 (en) Biologically active native biomatrix composition
DE69912952D1 (en) Cyclosporine
EP2308867A3 (en) 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses
IL164857A (en) 1-thia-4,8,diaza-spiro[4.5]decan-3-one compounds, process for preparation thereof and pharmaceutical compositions comprising them
EP2269657A3 (en) Prodrugs containing novel bio-cleavable linkers
WO2007076032A3 (en) Compositions and methods for producing a composition
EP2415760A3 (en) CCR-9 antagonists
WO2003095455A3 (en) Substituted pyrazolopyrimidines
EP2266622A3 (en) Prodrugs containing novel bio-cleavable linkers
ZA200403682B (en) N-adamantylmethyl derivatives and intermediates as pharmaceutical composition and processes for their preparation.
IL150225A0 (en) Lipopeptides, pharmaceutical compositions containing the same and methods for the production thereof
WO2009067686A8 (en) Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
WO2006058539A3 (en) Growth hormone secretagogue receptor 1a ligands
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
WO2005074970A3 (en) Neuroprotective dietary supplement
WO2007025988A3 (en) Liquid formulations of pegylated growth hormone
WO2002067865A3 (en) N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
MXPA05010613A (en) Parenteral formulation of mycophenolic acid, a salt or prodrug thereof.
EP1637167A3 (en) New injectable formulations containing progesterone
IL181216A0 (en) 3, 5-seco-4-norcholestane derivatives and pharmaceutical compositions containing the same
WO2004087652A3 (en) Imidazotriazine compounds
EP1619195A3 (en) Compounds isolated from gamboge resin having activity in inhibiting the growth of tumor/cancer cells and pharmaceutical compositions comprising the same